{"entity":{"id":"novelty-nobility","kind":"company","name":"Novelty Nobility","aka":["Novelty Nobility, Inc.","Novelty Nobility Inc."],"tldr":"Novelty Nobility is a Korean antibody company. Its cancer drug NN3201 is an antibody-drug conjugate, an antibody that carries a cell-killing drug, aimed at the c-Kit protein found on some stomach wall tumours (GIST), small cell lung cancer and other cancers.","summary":"Novelty Nobility Inc. is a clinical-stage antibody company in Pangyo, Seongnam, Gyeonggi-do, Korea, with a location in Cambridge, Massachusetts, and describes oncology as its primary therapeutic area, with programmes also in ophthalmology and immunology. Its PREXISE antibody discovery platforms produced NN3201, a fully human IgG1 antibody-drug conjugate against c-Kit (CD117) carrying an MMAE payload at a drug-to-antibody ratio of 4 through a site-specific cleavable linker, and NN2802, an anti-c-Kit monoclonal antibody for mast cell diseases that has completed a phase 1a study. Its first registered cancer trial, NCT06805825, a phase 1 dose-escalation and expansion study of NN3201 in c-Kit-expressing tumours including gastrointestinal stromal tumours, small cell lung cancer, adenoid cystic carcinoma, uveal melanoma, neuroendocrine tumours and chromophobe and clear cell renal cell carcinoma, was posted on ClinicalTrials.gov in February 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.noveltynobility.com/"},{"label":"Pipeline","url":"https://www.noveltynobility.com/pipeline/pipeline.php"},{"label":"ClinicalTrials.gov: phase 1 trial of NN3201 (NCT06805825)","url":"https://clinicaltrials.gov/study/NCT06805825"}],"tags":[],"related":[],"cancers":["gist","sclc","adenoid-cystic-carcinoma","uveal-melanoma","neuroendocrine","chromophobe-rcc","rcc"],"sections":["adcs"],"technologies":["adc","monoclonal-antibody"],"targets":["kit"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year and financing not stated on the pages read. The company home page links a Korean trade headline about a licence of its c-Kit ADC to a US biotech; the article was not read, so the deal is not described. The company says it has signed an underwriter for a listing, also from a headline only; stage is left as growth. Read on 29 October 2026."],"hq":"Seongnam","country":"KR","companyType":"biotech","website":"https://www.noveltynobility.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/novelty-nobility/","neighbours":{"cancer":[{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/"},{"id":"chromophobe-rcc","kind":"cancer","name":"Chromophobe renal cell carcinoma","route":"/cancers/chromophobe-rcc/"},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"}]}}